Recently, there has been a piece of news that is quite eye-catching.On November 19, 2025, the ADC biotechnology company Lifordi Immunotherapeutics announced the completion of a new round of strategic financing amounting to $42 million. The funds will primarily be used for ADCs beyond oncology—specifically, LFD-200, which targets VISTA, one of the most competitive emerging … Read more
Recently, there has been some news that is quite eye-catching.On November 19, 2025, ADC Biotechnology Company Lifordi Immunotherapeutics announced the completion of a new round of strategic financing of $42 million. The funds are mainly used for ADC beyond tumors— LFD-200, which targets VISTA, one of the most competitive emerging targets (for both cancer and … Read more
In 1966, a science fiction film titled Fantastic Voyage was released in the United States. In the film, to save a scientist whose brain blood vessels were damaged and in critical condition, five doctors were miniaturized to a fraction of a millimeter and injected into the body to travel to the brain to repair the … Read more
Abstract: Brain metastases (BMs) from lung cancer are one of the major factors contributing to poor prognosis in patients with non-small cell lung cancer (NSCLC). In recent years, antibody-drug conjugates (ADCs) have emerged as a new hope for treating HER2-mutant NSCLC due to their precise targeting and potent anti-tumor activity. This article focuses on the … Read more
Name: Ying’en Biotech-B Code: 09606.HK Current Stock Price: HKD 331.2 (as of the close on 2025/11/13) Market Capitalization: HKD 29.243 billion Industry: Biotechnology (ADC Drug Development) As a significant player in the global antibody-drug conjugate (ADC) field, Ying’en Biotech has rapidly advanced its core products and international collaboration strategies, achieving a year-on-year revenue growth of … Read more
1) The prognosis for refractory/relapsed LBCL not suitable for curative treatment is poor. The success of CD20×CD3 TCE mosunetuzumab combined with CD79b ADC polatuzumab vedotin in Phase 3 has provided patients with a novel, fixed-cycle, outpatient therapy. (Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial)In … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution of traditional drugs into precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution from traditional drugs to precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
Several high-value BD cases in 2025 have sparked strong interest in the Chinese biopharmaceutical sector from the capital market. China has become a major force in global BD output, thus examining the licensing pipelines of domestic biopharmaceutical companies can roughly analyze the direction of global pharmaceutical innovation. In the first half of this year, ADC … Read more
Compiled by: Oncology NewsSource: Oncology News In the field of lung cancer treatment, patients with EGFR-mutated non-small cell lung cancer (NSCLC) have long faced a “treatment desert” after developing resistance to TKI therapy, with traditional chemotherapy offering limited efficacy and significant side effects. The Chinese innovative drug, sacituzumab tirapazamine, developed by Professor Zhang Li’s team, … Read more